Global pharma and life sciences deals insights: Q2 2017

M&A market accelerates in value, despite declines in volume in Q2

After a series of declining values quarter-over-quarter throughout 2016, deal values have increased in both Q1 2017 and Q2 2017. While deal value is near a 2-year high, deal volume is the lowest it has been in the recent past. Megadeals have driven several of the recent quarterly deal values, including the acquisition of C.R. Bard in Q2 2017 for $25.7 billion, which comprised approximately one-third of the total deal value for the current quarter.


Medical devices and services lead M&A activity in Q2

Compared to historical periods, M&A values increased by 44% in Q2, driven primarily by the medical devices and services sectors which both saw strong deal activity.

Contact us

Glenn Hunzinger
US Pharmaceutical and Life Sciences Deals Leader
Tel: +1 (646) 471 8764

James Woods
Principal, US Deals
Tel: +1 (617) 530 4133

Follow us